摘要
目的探讨恩替卡韦联合乳酸杆菌治疗乙肝肝硬化的临床效果以及对患者肠道菌群的影响。方法选择本院2016年2月至2018年2月收治的乙肝肝硬化失代偿期患者76例作为研究对象,采用随机数表法将其分为实验组和对照组每组38例,给予对照组恩替卡韦治疗,给予实验组恩替卡韦联乳酸杆菌治疗,治疗6个月,评估两组患者肝功能恢复情况以及肠道目的菌群情况。结果实验组患者厌食、腹胀以及乏力改善率均明显高于对照组(P<0.05);两组患者治疗前各项肝功能指标无明显差异(P>0.05),治疗后,实验组ALT、TBIL、AST均明显低于对照组(P<0.05);两组治疗前各个菌群数目无明显差异(P>0.05),治疗后,实验组患者乳酸杆菌、双歧杆菌数目明显高于对照组(P<0.05),肠球菌、肠杆菌明显低于对照组(P<0.05)。结论恩替卡韦联合乳酸杆菌治疗乙肝肝硬化可显著改善患者症状以及肝功能,对改善肠道菌群效果明显,适合在临床上推广应用。
Objective To investigate the clinical effects of entecavir combined with lactobacillus in the treatment of hepatitis B cirrhosis and its effect on intestinal flora.Methods A total of 76 patients with decompensated hepatitis B cirrhosis admitted to our hospital from February 2016 to February 2018 were enrolled in the study.They were randomly divided into the experimental group and the control group,38 patients in each group.The group was treated with entecavir,and the experimental group was treated with entecavir-Lactobacillus for 6 months.The liver function recovery and intestinal flora were evaluated in the two groups.Results The anorexia,bloating and fatigue improvement rate of the experimental group were significantly higher than those of the control group(P<0.05).There was no significant difference in the liver function indexes between the two groups before treatment(P>0.05).After treatment,the experimental group ALT and TBIL The AST was significantly lower than that of the control group(P<0.05).There was no significant difference in the number of each group before treatment(P>0.05).After treatment,the number of Lactobacillus and Bifidobacteria in the experimental group was significantly higher than that in the control group(P<0.05).Enterococcus and Enterobacter were significantly lower than the control group(P<0.05).Conclusion Entecavir combined with lactobacillus in the treatment of hepatitis B cirrhosis can significantly improve the symptoms and liver function of patients,and has obvious effects on improving intestinal flora.It is suitable for clinical application.
作者
鲁欣
吉清
刘焕云
LU Xin;JI Qing;LIU Huan-yun(Chinese Medicine Hospital of Yubei District,Chongqing,401120,China)
出处
《中国地方病防治》
CAS
2019年第3期331-332,共2页
Chinese Journal of Control of Endemic Diseases
基金
2017重庆市卫生计生委医学科研项目(2017MSXM204)
关键词
恩替卡韦
乳酸杆菌
乙肝肝硬化
肠道菌群
Entecavir
Lactobacillus
Hepatitis B cirrhosis
Intestinal flora
